By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Serenex 

323 Foster Street

Durham  North Carolina  27701  U.S.A.
Phone: 919-281-6001 or 888-733-0033 Fax: 919-281-6050


SEARCH JOBS


Industry
Biotechnology






Company News
NC Judge Awards $57 Million to Durham Drug Company, Serenex 9/5/2008 7:18:43 AM
Coserics Announces Company Formation Including Spin-Out of Phase 2 Clinical Asset From Serenex 4/17/2008 11:02:19 AM
Serenex Announces Collaboration With National Cancer Institute to Initiate Clinical Trial With Serenex's Proprietary Small Molecule HSP90 Inhibitor, SNX-5422 2/27/2008 10:11:05 AM
Serenex Announces Collaboration With National Cancer Institute to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Lung Cancer 1/24/2008 9:44:50 AM
Multiple Myeloma Research Foundation (MMRF) Grants $3.5 Million in Biotech Investment Awards 1/23/2008 10:59:39 AM
Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease 1/17/2008 9:24:08 AM
Serenex Announces Initiation of Second Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422 12/4/2007 12:42:06 PM
Serenex to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference 10/23/2007 8:22:00 AM
Serenex to Present at Biotechnology Industry Organization (BIO) Investor Forum 2007 10/9/2007 8:38:46 AM
Serenex Announces Initiation of Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422 5/31/2007 10:02:48 AM
1234
//-->